DeepTech Startup Due Diligence: Investing in Frontier Science
Deep technology startups tackle problems that require genuine scientific or engineering breakthroughs. Unlike software companies, they can't be built in a weekend with an API — they demand years of R&D, specialized talent, and patient capital.
The DeepTech Landscape in 2026
DeepTech is experiencing a renaissance driven by convergence of computing power, materials science, and biotechnology:
- Quantum Computing — Moving from research labs to early commercial applications
- Advanced Materials — Graphene, metamaterials, and programmable matter
- Synthetic Biology — Engineering biological systems for industrial applications
- Robotics & Autonomous Systems — Beyond warehouse automation into unstructured environments
- Nuclear Energy — Small modular reactors and fusion approaching commercialization
Why DeepTech Is Different
The investment thesis for deep tech fundamentally differs from software:
- Longer development cycles — 5-10 years to commercialization vs. 1-2 for software
- Higher capital requirements — Lab equipment, manufacturing, regulatory approvals
- Stronger moats — IP, trade secrets, and tacit knowledge create near-impenetrable barriers
- Larger outcomes — DeepTech exits tend to be larger in absolute terms
What PV1 Evaluates in DeepTech
- Technology Readiness Level (TRL): Scale 1-9. Investors should target TRL 5+ for venture
- Team Scientific Credibility: Published research, patents, domain expertise
- Manufacturing Scalability: Can lab results translate to commercial production?
- IP Portfolio Strength: Patent breadth, freedom to operate, trade secret protection
- Runway to Milestones: Does funding last until next value-inflection point?
Key Metrics
- Patent Portfolio: Quality over quantity — broad claims in core technology
- Time to Revenue: Realistic timeline based on TRL progression
- Government Grant Revenue: Non-dilutive funding signals institutional validation
- Strategic Partnership Count: Industry partnerships de-risk commercialization
Risk Factors
- Technical Risk: The science may simply not work at scale
- Funding Gap: Deep tech often falls in the "valley of death" between grant funding and commercial revenue
- Talent Concentration: Key person risk is extreme when one scientist holds the IP
- Market Timing: Being 5 years too early is functionally identical to being wrong
Related Reading
.svg.svg)